Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that Dr. Daniel B. Carr, CEO and CMO, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's annual results for the period ending December 31, 2007. The call will be held Thursday, March 6, 2008 at 4:15 p.m. EST.

The Company invites all interested parties to participate. The call will be webcast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm. The call will be archived on the Company's website at: www.javelinpharmaceuticals.com.

CONFERENCE CALL ALERT

Date: March 6, 2008

Time: 4:15 p.m. E.S.T.

Please call: (877) 419-6593 Domestic OR (719) 325-4861 International

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject(TM), has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.

Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.